Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

IMPORTANCE: Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. Anti–programmed cell death 1 (PD-1) antibodies have antitumor activity in this disease, but little is known about the activity of anti–programmed cell death lig...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Hassan, Raffit, Thomas, Anish, Nemunaitis, John J., Patel, Manish R., Bennouna, Jaafar, Chen, Franklin L., Delord, Jean-Pierre, Dowlati, Afshin, Kochuparambil, Samith T., Taylor, Matthew H., Powderly, John D., Vaishampayan, Ulka N., Verschraegen, Claire, Grote, Hans Juergen, von Heydebreck, Anja, Chin, Kevin, Gulley, James L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439847/
https://ncbi.nlm.nih.gov/pubmed/30605211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5428
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados